Li J, Yang HI, Yeh ML, et al. - In patients suffering from chronic hepatitis B (CHB), researchers undertook this retrospective cohort analysis to assess how cirrhosis, hepatocellular carcinoma (HCC), and HBsAg seroclearance incidence could be impacted by fatty liver (FL). Participants were 6,786 adult CHB patients. By applying propensity score matching (PSM), FL-CHB (concurrent FL and CHB) and non-FL CHB groups were balanced. Prior to PSM, lower 10-year cumulative rates of cirrhosis, HCC, and a higher HBsAg seroclearance rate were reported in FL-CHB patients vs non-FL CHB. Experts observed comparable outcomes in the matched FL-CHB and non-FL CHB patients, as well as in the antiviral managed PSM cohort. Overall, findings demonstrated a significant association of FL with lower cirrhosis and HCC risk as well as with higher HBsAg seroclearance.